Synchronous colorectal adenocarcinoma and gastrointestinal stromal tumor in Meckel's diverticulum; an unusual association

Christopher Kosmidis*1, Christopher Efthimiadis1, Sofia Levva1, George Anthimidis1, Sofia Baka2, Marios Grigoriou1, Ioanna Tzeveleki3, Maria Masmanidou4, Thomas Zaramboukas5 and Georgios Basdanis3

Address: 1Department of Surgery, Interbalkan European Medical Center, Thessaloniki, Greece, 2Department of Oncology, Interbalkan European Medical Center, Thessaloniki, Greece, 31st Propedeutic Surgical Clinic, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece, 41st Propedeutic Clinic of Internal Medicine, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece and 5Pathology Department, Aristotle University of Thessaloniki, Thessaloniki, Greece

Email: Christopher Kosmidis* - dr.ckosmidis@gmail.com; Christopher Efthimiadis - efthimiadis_psihidis@yahoo.com; Sofia Levva - dr.slevva@gmail.com; George Anthimidis - georgeagg@vodafone.net.gr; Sofia Baka - baka sofia@hotmail.com; Marios Grigoriou - mgregoriou@gmail.com; Ioanna Tzeveleki - jotzevel@otenet.gr; Maria Masmanidou - s_levva@hotmail.com; Thomas Zaramboukas - diagnosis@the.forthnet.gr; Georgios Basdanis - basdanis@med.auth.gr

* Corresponding author

Abstract

Background: Coexistence of gastrointestinal stromal tumor with synchronous or metachronous colorectal cancer represents a phenomenon with increasing number of relative reports in the last 5 years. Synchronous occurrence of GISTs with other gastrointestinal tumors of different histogenesis presents a special interest. We herein report a case of GIST in Meckel's diverticulum synchronous with colorectal adenocarcinoma.

Case presentation: A 69 year old man, presented with abdominal distension and anal bleeding on defecation. Colonoscopy revealed colorectal cancer and a low anterior resection was performed, during which a tumor in Meckel's diverticulum was discovered. Histologic examination revealed GIST in Meckel's diverticulum and a rectosigmoid adenocarcinoma.

Conclusion: Whenever GIST is encountered, the surgeon should be alert to recognize a possible coexistent tumor with different histological origin. Correct diagnosis of synchronous tumors of different origin is the cornerstone of treatment.

Published: 23 March 2009

Received: 1 January 2009
Accepted: 23 March 2009

This article is available from: http://www.wjso.com/content/7/1/33

© 2009 Kosmidis et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background

Meckel's diverticulum is surgically removed only when a complication arises or a neoplasia develops. Neoplastic transformation has been reported, but gastrointestinal stromal tumors (GISTs) are exceptional in this location [1,2]. The management of GISTs has dramatically evolved over the last ten years. However, their coexistence with other gastrointestinal tumors of different histogenesis presents a special clinical problem. We herein report a case of GIST in Meckel's diverticulum synchronous with colorectal adenocarcinoma.

Case presentation

A 69 year-old-man presented with abdominal distension and anal bleeding on defecation. For the last six months the patient was complaining of flatulence, periumbilical
pain and sensation of incomplete evacuation. Apart from tenderness on deep palpation, blood on PR examination and increased bowel sounds, all other systems were found normal on clinical examination.

Colonoscopy revealed intraluminal stenosis of the colorectal junction and biopsy specimens were obtained. Biopsy confirmed a well differentiated mucinous adenocarcinoma of the rectosigmoid colon. There was no evidence of metastasis, based on abdominal computed tomography (CT), chest X-ray and endorectal ultrasound (US) 3D. Carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 19-9, and cancer antigen (CA) 50 were normal. Low anterior resection for colorectal carcinoma (CRC) with an end to end primary anastomosis was performed, while on exploration a mass in Meckel's diverticulum, 80 cm proximal to the ileocecal valve, was encountered (Figure 1). The mass was 7.5 cm in maximal diameter (Figure 2A, B), while the size of the Meckel's diverticulum was 3 cm. Thus, this case is classified as an “intermediate risk” GIST according to the risk assessment of aggressive behavior in GISTs proposed by Fletcher et al. (size: 7.5 cm, mitotic count: 0-1/50 HPF) [3]. No evidence of liver metastasis or intra-abdominal metastatic spread was found. The patient underwent resection of the tumor together with partial resection of the small bowel in order to avoid rupture and intra-abdominal spillage. Tumor was excised, together with 3 cm of ileum on either side, and a lateral to lateral anastomosis was performed with the use of staplers.

The lesion in the colorectal junction was a stage C2 (Astler-Coller) tumour, 8 x 6 cm in size (Figure 3), located in the rectosigmoid colon. Microscopic examination showed a well-differentiated adenocarcinoma, penetrating the bowel wall, without nerve and vascular invasion.

However, one of the 23 resected lymph nodes was positive for metastasis. According to the TNM (tumor, lymph nodes, metastasis) classification, the disease was stage IIIb. Histopathological examination of the resected Meckel's diverticulum tumor revealed a stromal cell neoplasm with a few necrotic and hemorrhagic areas and a low index of mitotic count (0–1 mitoses/50 HPF) (Figure 4A, B). Immunohistochemical analysis revealed expression of C-kit (strongly positive), moderately positive stain for SMA, while markers for focal S-100 and CD 34 were negative (Figure 5).

Patient's postoperative course was uneventful, and he was commenced on adjuvant chemotherapy with FOLFOX regimen (oxaliplatin i.v., 85 mg/m2(on day 1), leukovorin i.v., 200 mg/m2 (on days 1,2), 5 FU (fluorouracil) i.v., bolus 400 mg/m2 (on days 1,2), 5 FU i.v., 22 hours-infusion, 600 mg/m2 (on days 1,2), every 2 weeks for 12 cycles.

One year later he has no signs of local recurrence or metastasis.

Discussion

The term GIST was introduced by Mazur and Clark in 1983 in order to define a heterogeneous group of neoplasms of spindle and epithelioid cells arising from the stroma with no definite cell line of origin and varying patterns of differentiation [4,5]. GISTs are considered to be mesenchymal neoplasms, encompassing a majority of tumors previously considered gastrointestinal smooth muscle tumors, which, with the implementation of immunohistochemical stains and electron microscopy in recent years, have been recognized as a distinct pathological entity [3]. Their nomenclature, histogenesis, criteria for diagnosis, prognostic manifestations, and classification have raised much debate and controversy [6,7]. Though the most common mesenchymal tumors in the gastrointestinal tract wall, arising from Cajal’s cells, they are rare neoplasms accounting for less than 1% of all gastrointestinal tumors [3].

The most common sites are stomach (60%) and small intestine (30%). The average presentation is in the sixth decade [8]. Most GISTs (>90%) express CD117, the c-kit proto-oncogene protein that is a transmembrane receptor for the stem cell growth factor, and 70% to 80% express CD34, the human progenitor cell antigen; less often, these tumors stain positive for actin and desmin [9].

The three most important factors in determining malignancy are mitotic rate, tumor size and site [8,10-12]. Mitotic counts higher than 2 per 50 high-power fields imply an increased risk for local recurrence in small bowel GIST [10]. It is generally accepted that the criteria for pre-
dicting biological behavior may differ significantly with location. For example, gastric GISTs are less aggressive than those located in small bowel. In the small intestine there is an overall 39% tumor related mortality, twice that for gastric GISTs [8,13].

Smaller GISTs are often incidental findings during surgery, radiologic studies, or endoscopy. Coexisting stromal tumors are usually very small and are detected incidentally during gastrointestinal surgery for carcinomas [14]. In our case the patient presented with anal bleeding, which was attributed to the colorectal carcinoma. Preoperative evaluation did not reveal the unique coexistence of tumor in Meckel's diverticulum along with the rectosigmoid cancer, even though the tumor was large, 7.5 cm in maximal diameter.

The patient underwent an en-block resection of the tumor to avoid rupture and intra-abdominal spillage, as it is recommended [10]. He was commenced on adjuvant chemotherapy with oxaliplatin, leukovorin, and fluorouracil. Imatinib mesylate was not used since treatment of localized GIST is complete surgical excision, without dissection of lymph nodes [11,12] and adjuvant treatment with imatinib is still under consideration. Imatinib is the standard treatment if complete surgery is not feasible [11]. As the localized GIST was excised intact, there was no rationale to submit the patient to a treatment that should be continued indefinitely and the long-term success of which is limited by development of imatinib resistance via secondary mutations or clonal selection [11].

Despite the considerable development in the management of GISTs the last 10 years and the immense progress recently made in understanding the molecular biology of GISTs, little is yet known about their rare synchronous occurrence with tumors of different histogenesis. GISTs have been reported to occur synchronously with colon adenocarcinoma, gastric cancer, lymphoma and carcinoid [13,15-18]. The coexistence of GIST with either synchronous or metachronous colorectal cancer represents a rare

![Figure 2](image1.png)

**Figure 2**

A: The specimen of the GIST in Meckel's diverticulum. The arrow shows the diverticulum. B: Transverse section of the specimen of the GIST in Meckel's diverticulum and the proximal part of the ileum. The arrow shows the diverticulum.

![Figure 3](image2.png)

**Figure 3**

The specimen of the colorectal adenocarcinoma.

![Figure 4](image3.png)

**Figure 4**

A) Invasion of submucosa of small intestine from GIST (HE×200). B) Histologically, the GIST was composed of sheets of spindle cell with moderate to slight interstitial collagen (HE×200).
phenomenon with increasing number of relative reports in the last 5 years.

Although the synchronous occurrence of GIST and other abdominal malignancy seems to be just a coincidence, combined genetic deregulation or influenced neighboring tissues by the same carcinogen could be causative factors [17,19]. There are some data regarding the co-occurrence, the association and the potential common origin (genetic pathways of tumorigenesis), between GIST and other tumors [18-20]. The limited number of these cases cannot confirm the existence of a common factor in tumorigenesis of these histopathologically completely different tumors and further studies are needed to clarify the possible association.

Most of the published cases describe gastric stromal tumors synchronous with another gastric malignancy. Our case describes a concomitant GIST in Meckel’s diverticulum with a colorectal adenocarcinoma. As far as we could elicit from the literature, this is the first report of such tumor coexistence with regard to location.

Conclusion
The role of thorough abdominal exploration despite advanced preoperative imaging techniques cannot be overemphasized. In case of colorectal cancer, the doctor should bear in mind the possibility of coexistent tumor with different histological origin elsewhere in the GI tract.

Consent
Written informed consent was obtained from the patient for publication of this Case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
KC and EC and BG performed the operation and together with AG and GM contributed to the conception and design of the manuscript. LS, BS, MM, and TI analyzed and interpreted the patient data regarding the disease. AG and LS were major contributors in writing the manuscript. ZT carried out the histology and immunohistochemistry examination. All authors read and approved the final manuscript.

References
1. Haber JJ: Meckel’s diverticulum. Am J Surg 1947, 73:468-485.
2. Chandramohan K, Agarwal M, Gurjar G, Gatti RC, Patel MH, Trivedi P, Kohari KCL: Gastrointestinal stromal tumour in Meckel’s diverticulum. WJOS 2007, 5:50.
3. Fletcher CD, Berman J, Corless CL, Gorstein F, Lasota J, Longley B, Miettinen M, O’Leary Tj, Remotti H, Rubin BT, Shmookler B, Sobin LH, Weiss SW: Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002, 33:459-465.
4. Mazur MT, Clark HB: Gastric stromal tumors. Reappraisal of histogenesis. Am J Surg Pathol 1983, 7:507-519.
5. Feldman M, Scharschmidt BF, Seigenger MH: Seigenger & Fordtran’s Gastrointestinal and Liver Disease. 6th edition. Philadelphia: W.B. Saunders; 1998.
6. Hasegawa T, Matsuno Y, Shimoda T, Hirohashi S: Gastrointestinal stromal tumor: consistent CD117 immunostaining for diagnosis, and prognostic classification based on tumor size and MIB-1 grade. Hum Pathol 2002, 33:669-676.
7. Yamada T: Textbook of Gastroenterology 4th edition. Philadelphia: Lippincott Williams & Wilkins; 2003.
8. Miettinen M, Lasota J: Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis and differential diagnosis. Arch Pathol Lab Med 2006, 130:1466-1478.
9. De Matteo RP: The GIST of targeted cancer therapy: A tumor (gastrointestinal stromal tumor), a mutated gene (c-kit), and a molecular inhibitor (STI571). Ann Surg Oncol 2002, 9:831-839.
10. D’Amato G, Steinert DM, McAuliffe JC, Trent JC: Update on the biology and therapy of gastrointestinal stromal tumors. Cancer Control 2005, 12:44-56.
11. Casali PG, Jost L, Reichardt P, Schlemmer M, Blay JY, ESMO Guidelines Working Group: Gastrointestinal stromal tumours: ESMO clinical recommendations for diagnosis, treatment and follow up. Annals of Onc 2008, 19(S2):iii35-38.
12. Weber AG, Jovenin N, Lubrano D, Jourin J, Yaziji N, Bouche O, Diebold MD, Delattre JF: Outcome after surgical treatment of gastrointestinal stromal tumours. Gastroentrol Clin Biol 2007, 31:579-584.
13. Wronska M, Ziarkiewicz-Wroblewska B, Cebulski W, Slodkowski M, Wasutynski A, Krasnodebski IW: Synchronous occurrence of gastrointestinal stromal tumors and other primary gastrointestinal neoplasms. World J Gastroenterol 2006, 12:5360-5362.
14. Agaimy A, Wünsch PH, Sobin LH, Lasota J, Miettinen M: Occurrence of other malignancies in patients with gastrointestinal stromal tumors. Semin Diagn Pathol 2006, 23:120-129.
15. Kaffes A, Hughes L, Hollinshed J, Katalaris P: Synchronous primary adenocarcinoma, mucosa-associated lymphoid tissue lymphoma and a stromal tumor in a Helicobacter pylori-infected stomach. J Gastroenterol Hepatol 2002, 17:1033-1036.
16. Kovar E, Faluhelyi Z, Bogner B, Kalmar K, Horvath G, Torneczky T: Dual tumors in the GI tract: synchronous and metachronous
stromal (GIST) and epithelial/neuroendocrine neoplasms. Magy Onkol 2004, 48:315-321.

17. Maiorana A, Fante R, Cesinaro MA, Fano AR: Synchronous occurrence of epithelial and stromal tumors in the stomach: a report of 6 cases. Arch Pathol Lab Med 2000, 124:682-686.

18. Usui M, Matsuda S, Suzuki H, Hirata K, Ogura Y, Shiraishi T: Somatostatinoma of the papilla of Vater with multiple gastrointestinal stromal tumors in a patient with von Recklinghausen’s disease. J Gastroenterol 2002, 37:947-953.

19. Andea AA, Lucas C, Cheng JD, Adsay NV: Synchronous occurrence of epithelial and stromal tumors in the stomach. Arch Pathol Lab Med 2001, 125:318-319.

20. Sugimura T, Fujimura S, Baba T: Tumor production in the glandular stomach and alimentary tract of the rat by N-methyl-N’-nitro-N-nitrosoguanidine. Cancer Res 1970, 30:455-465.

21. Miettinen M, Makhlof HR, Sobin LH, Lasota J: Gastrointestinal stromal tumors (GISTs) of the jejunum and ileum: a clinicopathologic, immunohistochemical and molecular study of 906 cases prior to imatinib with long-term follow-up. Am J Surg Pathol 2006, 30:477-489.